Hepatitis B Virus-related Hepatocellular Carcinoma – An Update on Epidemiology, Risk Factors and Surveillance
Keywords:
Nucleotide analogue, Nucleoside analogue, Liver cancer, HBVAbstract
References
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, RL., Torre, LA., Jemal, A. (2018) Global cancer statistics 2018 GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 68:(6) 394- 424.
Liu, Z., Mao, X., Jiang, Y., Cai, N., Jin, L., Zhang, T., et al. (2019) Changing trends in the disease burden of primary liver cancer caused by specific etiologies in China. Cancer Med, 8(12): 5787-5799.
Jemal, A., Ward, EM., Johnson, CJ., Cronin, KA., Ma, J., Ryerson, B., et al. (2017) Annual Report to the Nation on the Status of Cancer 1975-2014 Featuring Survival. J Natl Cancer Inst, 109(9): djx030.
Petruzziello, A. (2018) Epidemiology of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Related Hepatocellular Carcinoma. Open Virol J, 12: 26-32.
World Health Organisation. Global Hepatitis Report, 2017. https://apps.who.int/iris/bitstream/handle/10665/25 5016/9789241565455-eng.pdf;jsessionid=30E3683D- A94B83FFD346CC2D2DFDA682?sequence=1
Jefferies, M., Rauff, B., Rashid, H., Lam, T., Rafiq, S. (2018) Update on global epidemiology of viral hepatitis and preventive strategies. World J Clin Cases, 6(13): 589-599.
Singal, AG., Lampertico, P., Nahon, P. (2020) Epidemiology and surveillance for hepatocellular carcinoma New trends. J Hepatol, 72(2): 250-261.
Cheung, KS., Seto, WK., Wong, DK., Lai, CL., Yuen, MF. (2017) Relationship between HBsAg HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy. J Viral Hepat, 24(8): 654-661.
Cheung, KS., Seto, WK., Wong, DK., Mak, LY., Lai, CL., Yuen, MF. (2017) Wisteria floribunda agglutinin positive human Mac 2 binding protein predicts liver cancer development in chronic hepatitis B patients under antiviral treatment. Oncotarget, 8(29): 47507-47517.
Seto, WK., Lau, EH., Wu, JT., Hung, IF., Leung, WK., Cheung, KS., et al. (2017) Effects of nucleoside analogue prescription for hepatitis B on the incidence of liver cancer in Hong Kong: a territory wide ecological study. Aliment Pharmacol Ther, 45(4): 501-509.
Kumar, M., Chauhan, R., Gupta, N., Hissar, S., Sakhuja, P., Sarin, SK. (2009) Spontaneous increases in alanine aminotransferase levels in asymptomatic chronic hepatitis B virus infected patients. Gastroenterology, 136(4): 1272- 1280.
Chen, YC., Chu, CM., Liaw, YF. (2010) Age specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology, 51(12): 435- 444.
Paul, S., Saxena, A., Terrin, N., Viveiros, K., Balk, EM., Wong, JB. (2016) Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy: A Systematic Review and Meta analysis. Ann Intern Med, 164(1): 30-40.
Cheung, KS., Seto, WK., Lai, CL., Yuen, MF. (2016) Prevention and management of hepatitis B virus reactivation in cancer patients. Hepatol Int, 10(3): 407-414.
Levrero, M., Zucman-Rossi, J. (2016) Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol, 64(1 Suppl): S84-S101.
Gerlich, WH. (2013) Medical virology of hepatitis B: how it began and where we are now. Virol J, 10: 239.
Wong, GL., Chan, HL., Yiu, KK., Lai, JW., Chan, VK., Cheung, KK., et al. (2013) Meta analysis: The association of hepatitis B virus genotypes and hepatocellular carcinoma. Aliment Pharmacol Ther, 37(5): 517-526.
Chan, HL., Tse, CH., Mo, F., Koh, J., Wong, VW., Wong, GL., et al. (2008) High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol, 26(2): 177-182.
Sanchez-Tapias, JM., Costa, J., Mas, A., Bruguera, M., Rodés, J. (2002) Influence of hepatitis B virus genotype on the long term outcome of chronic hepatitis B in western patients. Gastroenterology, 123(6): 1848-1856.
Brechot, C., Gozuacik, D., Murakami, Y., Bréchot, PP. (2000) Molecular bases for the development of hepatitis B virus (HBV) related hepatocellular carcinoma (HCC). Semin Cancer Biol, 10(3): 211-231.
Kuang, SY., Jackson, PE., Wang, JB., Lu, PX., Muñoz, A., Qian, GS., et al. (2004) Specific mutations of hepatitis B virus in plasma predict liver cancer development. Proc Natl Acad Sci USA, 101(10): 3575-3580.
Liu, S., Zhang, H., Gu, C., Yin, J., He, Y., Xie, J., et al. (2009) Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta analysis. J Natl Cancer Inst, 101(15): 1066-1082.
Wang, HC., Huang, W., Lai, MD., Su, IJ. (2006) Hepatitis B virus pre S mutants endoplasmic reticulum stress and hepatocarcinogenesis. Cancer Sci, 97(8): 683-688.
Lucifora, J., Arzberger, S., Durantel, D., Belloni, L., Strubin, M., Levrero, M., et al. (2011) Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J Hepatol, 55(5): 996-1003.
Slagle, BL., Bouchard, MJ. (2016) Hepatitis B Virus X and Regulation of Viral Gene Expression. Cold Spring Harb Perspect Med, 6(3): a021402.
Xie, Y. (2017) Hepatitis B Virus-Associated Hepatocellular Carcinoma. Adv Exp Med Biol, 1018: 11-21.
Yuen, MF., Wong, DK., Fung, J., Ip, P., But, D., Hung, I., et al. (2008) HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology, 135(4): 1192-1199.
Lai, CL., Yuen, MF. (2007) The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med, 147(1): 58-61.
Udompap, P., Kim, WR. (2020) Development of Hepatocellular Carcinoma in Patients With Suppressed Viral Replication: Changes in Risk Over Time. Clin Liver Dis (Hoboken), 15(2): 85-90.
Chen, CJ., Yang, HI., Su, J., Jen, CH., You, SL., Lu, SN., et al. (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA, 295(1): 65-73.
Yang, HI., Lu, SN., Liaw, YF., You, SL., Sun, CA., Wang, LY., et al. (2002) Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med, 347(3): 168-174.
Ozakyol, A. (2017) Global Epidemiology of Hepatocellular Carcinoma (HCC Epidemiology). J Gastrointest Cancer, 48(3): 238-240.
Chen, CJ., Yang, HI. (2011) Natural history of chronic hepatitis B Revealed. J Gastroenterol Hepatol, 26(4): 628-638.
Raffetti, E., Fattovich, G., Donato, F. (2016) Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta analysis. Liver Int, 36(9): 1239-1251.
Zhang, H., Zhai, Y., Hu, Z., Wu, C., Qian, J., Jia, W., et al. (2010) Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet, 42(9): 755- 758.
Chan, KY., Wong, CM., Kwan, JS., Fong, Lee, JM., Cheung, KW., Yuan, MF., et al. (2011) Genome-wide association study of hepatocellular carcinoma in Southern Chinese patients with chronic hepatitis B virus infection. PLoS One, 6(12); e28798.
Schwabe, RF., Greten, TF. (2020) Gut microbiome in HCC - Mechanisms, diagnosis and therapy. J Hepatol, 72(2): 230-238.
Simon TG, Duberg AS, Aleman S, Chung, RT., Chan, AT., Ludvigsson, JF. (2020) Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality. N Engl J Med, 382: 1018-1028.
Chen H, Cai W, Chu ESH, Tang, J., Wong, CC., Wong, SH., et al. (2017) Hepatic cyclooxygenase-2 overexpression induced spontaneous hepatocellular carcinoma formation in mice. Oncogene, 36(31): 4415-4426.
Fodera, D., D'Alessandro, N., Cusimano, A., Poma, P., Notarbartolo, M., Lampiasi, N., et al. (2004) Induction of apoptosis and inhibition of cell growth in human hepatocellular carcinoma cells by COX-2 inhibitors. Ann N Y Acad Sci, 1028: 440-449.
Simon, TG., Duberg, AS., Aleman, S., Hangstrom, H., Nguyen, LH., Khalili, H., et al. (2019) Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population. Ann Intern Med, 171(5): 318-327.
Li, X., Sheng, L., Liu, L., Hu, Y., Chen, Y., Lou, L. (2020) Statin and the risk of hepatocellular carcinoma in patients with hepatitis B virus or hepatitis C virus infection: a meta-analysis. BMC Gastroenterol, 20: 98.
Facciorusso, A., Abd El Aziz, MA., Singh, S., Puseddu, S., Milione, M., Giacomelli, L. (2020) Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis. Cancers (Basel), 12(4): 874.
Cunha, V., Cotrim, HP., Rocha, R., Carvalhoe, K., Kusterer, LL. (2020) Metformin in the prevention of hepatocellular carcinoma in diabetic patients: A systematic review. Ann Hepatol, 19(3): 232-237.
Luo, Z., Zang, M., Guo, W. (2010) AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol, 6(3): 457-470.
Tan, Y., Wei, S., Zhang, W., Yang, J., Yang, J., Yan, L. (2019) Type 2 diabetes mellitus increases the risk of hepatocellular carcinoma in subjects with chronic hepatitis B virus infection: a meta-analysis and systematic review. Cancer Manag Res, 11: 705-713.
Li, CI., Chen, HJ., Lai, HC., Liu, CS., Lin, WY., Li, TC., et al. (2015) Hyperglycemia and chronic liver diseases on risk of hepatocellular carcinoma in Chinese patients with type 2 diabetes--National cohort of Taiwan Diabetes Study. Int J Cancer, 136(11): 2668-2679.
Moctezuma-Velazquez, C., Kalainy, S., Abraldes, JG. (2017) Beta-blockers in patients with advanced liver disease: Has the dust settled? Liver Transpl, 23(8): 1058-1069.
Thiele, M., Albillos, A., Abazi, R., Weist, R., Gluud, LL., Krag, A. (2015) Non-selective beta-blockers may reduce risk of hepatocellular carcinoma: a meta-analysis of randomized trials. Liver Int, 35(8): 2009-2016.
Tamura, T., Hishida, A., Wakai, K. (2019) Coffee consumption and liver cancer risk in Japan: a meta-analysis of six prospective cohort studies. Nagoya J Med Sci, 81(1): 143- 150.
Shimazu, T., Tsubono, Y., Kuriyama, S., Ohmori, K., Koizumi, Y., Nishino, Y., et al. (2005) Coffee consumption and the risk of primary liver cancer: pooled analysis of two prospective studies in Japan. Int J Cancer, 116(1): 150- 154.
Chen, CL., Chang, WC., Yi, CH., Hung, JS., Liu, TT., Lei, WY. et al. (2019) Association of coffee consumption and liver fibrosis progression in patients with HBeAg-negative chronic hepatitis B: A 5-year population-based cohort study. J Formos Med Assoc, 118(2): 628-635.
Jang, ES., Jeong, SH., Lee, SH., Hwang,, SH., Ahn, SY., Lee, J., et al. (2013) The effect of coffee consumption on the development of hepatocellular carcinoma in hepatitis B virus endemic area. Liver Int, 33: 1092-1009.
Kao, JH., Chen, DS. (2002) Global control of hepatitis B virus infection.Lancet Infect Dis, 2(7): 395-403.
Poland, GA., Jacobson, RM. (2004) Clinical practice: prevention of hepatitis B with the hepatitis B vaccine. N Engl J Med, 351(27): 2832-2838.
Hepatitis B vaccines: WHO position paper - July 2017. Wkly Epidemiol Rec 2017;92:369-92.
Pan, CQ., Duan, Z., Dai, E., Zhang, S., Han, G., Wang, Y., et al. (2016) Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load. N Engl J Med, 374(24): 2324-34.
Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1991;40:1-25.
Marcellin, P., Gane, E., Buti, M., Sievert, W., Jacobson, IM., Washington, MK., et al. (2013) Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet, 381(9865): 468-475.
Hosaka, T., Suzuki, F., Kobayashi, M., Seko, Y., Kawamura, Y., Sezaki, H., et al. (2013) Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology, 58(1): 98- 107.
Wu, CY., Lin, JT., Ho, HJ., Su, CW., Lee, TY., Wang, SY., et al. (2014) Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Gastroenterology, 147(1): 143-151.
Lai, CL., Yuen, MF. (2013) Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology, 57(1): 399-408.
European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67:370-398.
Cheung, KS., Mak, LY., Liu, SH., Cheng, HM., Seto, WK., Yuen, MF., et al. (2020) Entecavir vs Tenofovir in Hepatocellular Carcinoma Prevention in Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis. Clin Transl Gastroenterol, 11(10): e00236.
Murata, K., Asano, M., Matsumoto, A., Sugiyama, M., Nishida, N., Tanaka, E., et al. Induction of IFN-lambda3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection. Gut, 67(2): 362- 371.
Sato, A., Ohtsuki, M., Hata, M., Kobayashi, E., Murakami, T. (2006) Antitumor activity of IFN-lambda in murine tumor models. J Immunol,176(12): 7686-7694.
Woo, G., Tomlinson, G., Nishikawa, Y., Kowgier, M., Sherman, M., Wong, DKH., et al. (2010) Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology, 139(4): 1218-1229.
Seto, WK., Lo, YR., Pawlotsky, JM., Yuen, MF. (2018) Chronic hepatitis B virus infection. Lancet, 392(10161): 2313- 2324.
Cheung, KS., Leung, WK., Seto, WK.(2019) Application of Big Data analysis in gastrointestinal research. World J Gastroenterol, 25(24): 2990-3008.
European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. (2018) EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol, 69(1): 182-236.
Papatheodoridis, GV., Lampertico, P., Manolakopoulos, S., Lok, A. (2010) Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol, 53(2): 348-356.
Cornberg, M., Lok, AS., Terrault, NA., Zoulim, F. (2019) Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. Hepatology.
Voulgaris, T., Papatheodoridi, M., Lampertico, P., Papatheodoridis, GV. (2020) Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B. Liver Int, 40(3): 484-495.
Arguedas, MR., Chen, VK., Eloubeidi, MA., Fallon, MB. (2003) Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol, 98(3): 679-690.
Giannini, EG., Cucchetti, A., Erroi, V., Garuti, F., Odaldi, F., Trevisani, F. (2013) Surveillance for early diagnosis of hepatocellular carcinoma: how best to do it? World J Gastroenterol, 19(47): 8808-8821.
Poustchi, H., Farrell, GC., Strasser, SI., Lee, AU., McCaughan, GW., George, J. (2011) Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed? Hepatology, 54(6): 1998-2004.
Singal, AG., Pillai, A., Tiro, J. (2014) Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med, 11(4): e1001624.
Zhang, BH., Yang, BH., Tang, ZY. (2004) Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol, 130(7): 417-422.
Sarasin, FP., Giostra, E., Hadengue, A. (1996) Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med, 101(4): 422-434.
Tzartzeva, K., Obi, J., Rich, NE., Parikh, ND., Marrero, JA., Yopp, A., et al. (2018) Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. Gastroenterology, 154(6): 1706-1718 e1.
Simmons, O., Fetzer, DT., Yokoo, T., Marrero, JA., Yopp, A., Kono, Y., et al. (2017) Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment Pharmacol Ther, 45(1):169- 177.
Biselli, M., Conti, F., Gramenzi, A., Frigerio, M., Cucchetti, A., Fatti, G., et al. (2005) A new approach to the use of alpha-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. Br J Cancer, 112(1): 69-76.
Papatheodoridis, GV., Idilman, R., Dalekos, GN., Buti, M., Chi, H., van Boemmel, F., et al. (2017) The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology, 66(5): 1444-1453.
Yuen, MF., Tanaka, Y., Fong, DY., Fung, J., Ka-Ho Wong, D., Chi-Hang Yuen, J., et al. (2009) Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol, 50(1): 80-88.
Wong, VW., Chan, SL., Mo, F., Ching Chan, T., Ho-Fung Loong, H., Lai-Hung Wong, G., et al. (2010) Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol, 28(10): 1660-1665.
Yang, HI., Yuen, MF., Chan, HL., Hyub Han, K., Jer Chen, P., Kim, DY., et al. (2011) Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol,12(6): 568-574.
Lee, MH., Yang, HI., Liu, J., Batrla-Utermann, R., Jen, CL., Iloeje, UH., et al. (2013) Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology, 58(2): 546-554.
Kim, DY., Song, KJ., Kim, SU., Yoo, EJ., Park, JY., Ahn, SH., et al. (2013) Transient elastography-based risk estimation of hepatitis B virus-related occurrence of hepatocellular carcinoma: development and validation of a predictive model. Onco Targets Ther, 6: 1463-1469.
Wong, GL., Chan, HL., Wong, CK., Leung, C., Chan, CY., Po- Lai Ho, P., et al. (2014) Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. J Hepatol, 60(2): 339-345.
Shin, SH., Kim, SU., Park, JY., Kim, DY., Ahn, SH., Han, KW., et al. (2015) Liver stiffness-based model for prediction of hepatocellular carcinoma in chronic hepatitis B virus infection: comparison with histological fibrosis. Liver Int, 35(): 1054-1062.
Poh, Z., Shen, L., Yang, HI., Seto, WK., Wong,VW., Lin, CY., et al. (2016) Real-world risk score for hepatocellular carcinoma (RWS-HCC): a clinically practical risk predictor for HCC in chronic hepatitis B. Gut, 65(5): 887-888.
Fan, C., Li, M., Gan, Y., Chen, T., Sun, Y., Lu, J., et al. (2019) A simple AGED score for risk classification of primary liver cancer: development and validation with long-term prospective HBsAg-positive cohorts in Qidong, China. Gut, 68(5): 948-949.
Sinn, DH., Lee, JH., Kim, K., Ahn, JH., Lee, JH., Kim, JE., et al. (2017) A Novel Model for Predicting Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B and Normal Alanine Aminotransferase Levels. Gut Liver, 11(4): 528-534.
Paik, N., Sinn, DH., Lee, JH., Oh, IS., Kim, JH., Kang, W., et al. (2018) Non-invasive tests for liver disease severity and the hepatocellular carcinoma risk in chronic hepatitis B patients with low-level viremia. Liver Int, 38(1): 68-75.
Fung, J., Cheung, KS., Wong, DK., Mak, LY., To, WP., Seto, WK., et al. (2018) Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance. Hepatology, 68(2): 462-472.
Lee, HW., Yoo, EJ., Kim, BK., Kim, SU., Park, JY., Kim, DY., et al. (2014) Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy. Am J Gastroenterol, 109(8): 1241-1249.
Papatheodoridis, G., Dalekos, G., Sypsa, V., Yurdaydin, C., Buti, M., Goulis, J., et al. (2016) PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol, 6(4): 800-806.
Sohn, W., Cho, JY., Kim, JH., Lee, JI., Kim, HJ., Woo, AH., et al. (2017) Risk score model for the development of hepatocellular carcinoma in treatment-naive patients receiving oral antiviral treatment for chronic hepatitis B. Clin Mol Hepatol, 23(2): 170-178.
Chen, CH., Lee, CM., Lai, HC., Hu, TH., Su, WP., Lu, SN., et al. (2017) Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir. Oncotarget, 8(54): 92431-92441.
Hsu, YC., Yip, TC., Ho, HJ., Wong, VW., Huang, VT., et al. (2018) Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. J Hepatol, 69(2): 278-285.
Kim, JH., Kim, YD., Lee, M., Jun, BG., Kim, TS., Suk, KT., et al. (2018) Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy. J Hepatol, 69(5): 1066-1073.
Yu, JH., Suh, YJ., Jin, YJ., Heo. NY., Jang, JW., You, CR., et al. (2019) Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovir. Eur J Gastroenterol Hepatol, 31(7): 865-872.
